Fundraising Fox
Isomab
Nottingham, GB · Founded 2022 · 15 employees on LinkedIn · 1 known investors
Find your way into Isomab
Sign up to see every warm intro you have to Isomab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Isomab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Isomab develops first-in-class antibody therapies targeting specific VEGF-A isoforms to restore blood vessel growth and improve blood flow in cardiovascular diseases. The company was spun out of the University of Nottingham in 2022 and builds on over 20 years of vascular biology research.
Investors · 1
How we know: Broadview Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- ISOMAB LTD
- Company number
- 13972139
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 11 Mar 2022
- Registered office
- St Johns Innovation Centre, Cowley Road, Cambridge, CB4 0WS
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 10 Mar 2026 · next due 24 Mar 2027
Current officers · 9
- Julian Michael Stuart Attfield — secretary, appointed 24 Jul 2025
- David Owen Bates — director, appointed 11 Mar 2022
- Philip Henrik Engell Brainin — director, appointed 12 Mar 2026
- Paul Martin Edwards — director, appointed 1 Jul 2022
- Shi Yin Foo — director, appointed 17 Feb 2025
- Anker Lundemose — director, appointed 1 Apr 2024
- JR Needham — director, appointed 12 Feb 2024
- John Martin Williams — director, appointed 4 Jun 2026
- Mercia Fund Management (nominees) Limited — corporate director, appointed 12 Feb 2024
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Isomab do?
- Isomab develops first-in-class antibody therapies targeting specific VEGF-A isoforms to restore blood vessel growth and improve blood flow in cardiovascular diseases. The company was spun out of the University of Nottingham in 2022 and builds on over 20 years of vascular biology research.
- Who are Isomab's investors?
- Isomab's investors include Broadview Ventures.
- Where is Isomab headquartered?
- Isomab is headquartered in Nottingham, GB.